Showing 1,521 - 1,540 results of 13,341 for search '(( significant increase decrease ) OR ( significant substantial decrease ))', query time: 0.56s Refine Results
  1. 1521
  2. 1522

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  3. 1523

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  4. 1524

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  5. 1525
  6. 1526
  7. 1527
  8. 1528
  9. 1529
  10. 1530
  11. 1531
  12. 1532
  13. 1533
  14. 1534
  15. 1535
  16. 1536
  17. 1537
  18. 1538
  19. 1539
  20. 1540